top of page
News, Events and Updates
Search
Aug 14, 2013
Anavex CEO Writes Letter to Shareholders
Jul 7, 2013
Anavex Raises $2.6M in Private Placement and Conversion of Liabilities, Enters into $10M Financing
May 5, 2013
Anavex Invited to File Funding Application for Phase 2a Clinical Trial of ANAVEX 2-73
Mar 17, 2013
Anavex Comments on FDA Plan to Expedite Approval of New Alzheimer's Drugs
Mar 11, 2013
ANAVEX 2-73 Restores Mitochondrial Functionality, Clocks Cell Death and Oxidative Stress
Mar 6, 2013
Mitochondrial Protection in Mouse Hippocampus against Aβ25-35 Toxicity is Induced by the Novel...
Feb 4, 2013
Anavex Retains Novak Druce Connolly Bove & Quigg; Maximize Value of Intellectual Property Portfolio
Jan 11, 2013
Amyloid Toxicity Induced by Oligomeric Aβ25-35 Injection Enhanced after Pharmacologic or Genetic...
Jan 11, 2013
Implication of the σ1 Chaperone Protein in Adult Neurogenesis: Contribution to Neuroprotection?
Jan 10, 2013
Anavex Appoints Tom Skarpelos as Director
Oct 17, 2012
ANAVEX 2-73 Shown to Block Oxidative Stress, Preventing Onset of Alzheimer's Disease
40
41
42
43
44
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
